cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Caribou Biosciences
12 own
9 watching
Current Price
$4.7
$-0.21
(-4.38%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
274.12M
52-Week High
52-Week High
11.52000
52-Week Low
52-Week Low
3.96000
Average Volume
Average Volume
1.1M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization274.12M
icon52-Week High11.52000
icon52-Week Low3.96000
iconAverage Volume1.1M
iconDividend Yield--
iconP/E Ratio--
What does the Caribou Biosciences do?
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
Read More
How much money does Caribou Biosciences make?
News & Events about Caribou Biosciences.
Ticker Report
3 months ago
Caribou Biosciences (NASDAQ:CRBU Get Rating) and Vir Biotechnology (NASDAQ:VIR Get Rating) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings...
Business Wire
3 months ago
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Caribou Biosciences, Inc. (NASDAQ: CRBU) on behalf of long-term stockholders following a class action complaint that was filed against Caribou on April 11, 2023 with a...
Globe Newswire
4 months ago
SAN DIEGO, May 02, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ: CRBU) Johnson Fistel, LLP is investigating potential claims on behalf of Caribou Biosciences, Inc. ("Caribou" or the "Company") (NASDAQ: CRBU) against certain of its officers and directors. If you are a current, long-term...
Globe Newswire
5 months ago
-- CB-012 genome-edited armoring strategy significantly reduced tumor burden and improved overall survival in AML xenograft models -- -- CB-012 IND-enabling studies ongoing; IND submission in r/r AML planned for H2 2023 -- BERKELEY, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc...
Globe Newswire
5 months ago
NEW YORK, April 10, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Caribou Biosciences, Inc. ("Caribou" or the "Company") (NASDAQ: CRBU) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Caribou investors who were adversely...
Frequently Asked Questions
Frequently Asked Questions
What is Caribou Biosciences share price today?
plus_minus_icon
Can Indians buy Caribou Biosciences shares?
plus_minus_icon
How can I buy Caribou Biosciences shares from India?
plus_minus_icon
Can Fractional shares of Caribou Biosciences be purchased?
plus_minus_icon
What are the documents required to start investing in Caribou Biosciences stocks?
plus_minus_icon
What is today’s traded volume of Caribou Biosciences?
plus_minus_icon
What is today’s market capitalisation of Caribou Biosciences?
plus_minus_icon
What is the 52-Week High and Low Range of Caribou Biosciences?
plus_minus_icon
What percentage is Caribou Biosciences down from its 52-Week High?
plus_minus_icon
What percentage is Caribou Biosciences up from its 52-Week Low?
plus_minus_icon
Current Price
$4.7
$-0.21
(-4.38%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00